It was only this past July that a phase 2 clinical trial showed positive results for patients with relapsing-remitting multiple sclerosis (RRMS) taking siponimod.
Now researchers have evaluated the drug’s efficacy in treating secondary progressive multiple sclerosis (SPMS) in a phase 3 trial. A collaborative team spanning from Europe, the United States, and Canada conducted this study as there is a need for treatments to delay disability onset in SPMS. Presented as late breaking news at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2016) in London, England, the researchers said that the EXPAND is the largest randomized, controlled study for this condition.
Siponimod, also called BAF312, is an orally active selective modulator of the sphinegosine-1 phosphate receptor subtypes 1 and 5. With the goal to analyze efficacy, safety, and tolerability of the drug, a total of 1,363 patients with SPMS were gathered from more than two dozen countries. SPMS was identified as progressive increase in disability for at least six months with an absence or independent of relapses. Patients ranged from 18 to 60 years old had Expanded Disability Status Scale (EDSS) scores from 3.0 to 6.5… [Read More]
MS Unites has been approved by MD Magazine to help bring awareness and attention to their high-quality news and informational peer exchange video’s they are creating for the global multiple sclerosis community.